GET DAILY SIGNALSTeleflex (TFX) Delivers +39.2% Adjusted EPS Growth in Q3 Amid Portfolio Shift
Key Takeaways
- Teleflex reported third-quarter revenue from continuing operations of $567.8 million, up 0.2% year over year on a reported basis and 3.0% on a pro forma adjusted constant-currency basis.
- Adjusted diluted earnings per share (EPS) from continuing operations rose to $2.63, up 39.2% from $1.89 in the prior-year period and ahead of management's expectations.
- GAAP diluted EPS from continuing operations was $1.30, compared with a loss of $1.32 a year earlier.
- Vascular and Surgical delivered solid growth, while the Interventional segment returned to modest growth as integration of the acquired Vascular Intervention business progressed.
- Teleflex raised its full-year 2026 adjusted diluted EPS guidance to a range of $7.50 to $7.75 while maintaining its pro forma adjusted constant-currency revenue growth outlook of 3.5% to 4.5%.
- The company repurchased approximately $350 million of common stock during the period, with $400 million remaining under its $1 billion authorization.
Earnings Context and Why It Matters
Teleflex is navigating a broad portfolio transformation, and the third-quarter results provide a clearer picture of how those efforts are playing out in the numbers. The company has already exited its OEM business and is moving toward closing the sales of its Acute Care and Interventional Urology units while integrating the Vascular Intervention business acquired from BIOTRONIK. In this setting, the quarter stands out less for top-line growth and more for signs of expanding margins, stronger earnings power, and sustained demand in the core procedure-driven businesses. With 2026 positioned as a transition year, these figures help show whether the streamlined Teleflex is on track for the earnings improvement targeted for 2027.
Reported Results
For the third quarter ended September 30, 2026, TFX posted revenue from continuing operations of $567.8 million, a 0.2% reported increase and a 3.0% rise on a pro forma adjusted constant-currency basis. Adjusted diluted EPS from continuing operations reached $2.63, up 39.2% from $1.89 a year earlier, while GAAP diluted EPS was $1.30 versus a prior-year loss of $1.32. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
By segment, Vascular generated $243.5 million (up 4.6% on a constant-currency basis), Surgical contributed $114.0 million (up 5.1%), and Interventional produced $210.3 million, returning to modest growth of 0.2% as integration activities progressed. Adjusted gross margin expanded to 66.8%, aided in part by a $25.3 million benefit from IEEPA tariff refunds, and adjusted operating margin rose to 25%.
Teleflex increased its full-year 2026 adjusted diluted EPS guidance to $7.50 to $7.75 and raised its GAAP EPS outlook to $2.84 to $3.09, while maintaining its constant-currency revenue growth guidance of 3.5% to 4.5%.
Market Reaction and Investor Sentiment
Heading into the report, attention centered on whether TFX could show real progress on its transformation, especially in the Interventional business and on margin expansion. The results delivered on both counts: adjusted EPS rose sharply, adjusted operating margin expanded, and management raised its full-year earnings outlook. GAAP EPS of $1.30 came in just below the consensus estimate of $1.32, though the much stronger adjusted figure of $2.63 highlights the company’s focus on non-GAAP measures. Investors also weighed ongoing confidence in closing the Acute Care and Interventional Urology divestiture, even if regulatory timing could stretch into 2027.
Forward Outlook and Key Factors to Monitor
Looking ahead, the raised guidance signals improving earnings momentum, yet execution risk remains the key theme. The most immediate catalyst is completion of the Acute Care and Interventional Urology divestiture to Intersurgical, which management expects by year-end subject to regulatory review. Any delay into 2027 would defer the related capital-allocation benefits and the more focused operating model.
Investors should continue to follow the Interventional segment’s path. Management has highlighted progress on customer conversions, distributor transitions, and sales-force territory openings, but sustained gains will depend on steady integration work. Capital returns stay in focus as well: TFX has outlined roughly $1 billion in share repurchases and $800 million in debt reduction linked to divestiture proceeds.
Longer-term growth platforms also warrant attention. EZPLAZ, the first and only FDA-licensed freeze-dried plasma, carries a potential U.S. market opportunity of at least $200 million, while Freesolve, a resorbable magnesium scaffold, recently received FDA Breakthrough Device Designation for PCI. These initiatives are unlikely to affect near-term results materially but could influence the company’s growth profile in the years ahead.
Using Tickeron’s AI Screener in My Research
I often turn to Tickeron’s AI Screener when evaluating medical-device names like TFX alongside broader market trends. The tool helps me quickly filter for technical patterns, fundamentals, and performance metrics, surfacing ideas that complement traditional analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TFX in upward trend: 10-day moving average moved above 50-day moving average on October 27, 2026
The 10-day moving average for TFX crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TFX as a result. In 49 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for TFX just turned positive on October 01, 2026. Looking at past instances where TFX's MACD turned positive, the stock continued to rise in 29 of 51 cases over the following month. The odds of a continued upward trend are 57%.
TFX moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where TFX advanced for three days, in 166 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
The Aroon Indicator entered an Uptrend today. In 106 of 202 cases where TFX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TFX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
TFX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (5.069). P/E Ratio (-6.502) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.165) is also within normal values, averaging (4.143). Dividend Yield (0.009) settles around the average of (0.005) among similar stocks. P/S Ratio (2.508) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. TFX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical devices for critical care, urology and surgery
Industry PharmaceuticalsOther
Advertisement